175 related articles for article (PubMed ID: 22696019)
1. Does the piperacillin minimum inhibitory concentration for Pseudomonas aeruginosa influence clinical outcomes of children with pseudomonal bacteremia?
Tamma PD; Turnbull AE; Milstone AM; Hsu AJ; Carroll KC; Cosgrove SE
Clin Infect Dis; 2012 Sep; 55(6):799-806. PubMed ID: 22696019
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint.
Tam VH; Gamez EA; Weston JS; Gerard LN; Larocco MT; Caeiro JP; Gentry LO; Garey KW
Clin Infect Dis; 2008 Mar; 46(6):862-7. PubMed ID: 18279040
[TBL] [Abstract][Full Text] [Related]
3. A propensity score-matched analysis of the impact of minimum inhibitory concentration on mortality in patients with Pseudomonas aeruginosa bacteraemia treated with piperacillin/tazobactam.
Gentry CA; Williams RJ
Int J Antimicrob Agents; 2017 Mar; 49(3):333-338. PubMed ID: 28108367
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
Kim HS; Park BK; Kim SK; Han SB; Lee JW; Lee DG; Chung NG; Cho B; Jeong DC; Kang JH
BMC Infect Dis; 2017 Jul; 17(1):500. PubMed ID: 28716109
[TBL] [Abstract][Full Text] [Related]
5. Investigation of the clinical breakpoints of piperacillin-tazobactam against infections caused by Pseudomonas aeruginosa.
Yamagishi Y; Terada M; Ohki E; Miura Y; Umemura T; Mikamo H
J Infect Chemother; 2012 Feb; 18(1):127-9. PubMed ID: 21814800
[TBL] [Abstract][Full Text] [Related]
6. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis.
Zelenitsky SA; Harding GK; Sun S; Ubhi K; Ariano RE
J Antimicrob Chemother; 2003 Oct; 52(4):668-74. PubMed ID: 12951354
[TBL] [Abstract][Full Text] [Related]
7. A five-year review of Pseudomonas aeruginosa bacteremia in children hospitalized at a single center in southern China.
Zhang Q; Smith JC; Zhu Q; Guo Z; MacDonald NE
Int J Infect Dis; 2012 Aug; 16(8):e628-32. PubMed ID: 22709682
[TBL] [Abstract][Full Text] [Related]
8. A propensity score-matched analysis of the impact of minimum inhibitory concentration on mortality in patients with Pseudomonas aeruginosa bacteremia treated with cefepime or ceftazidime.
Ratliff AR; Gentry CA; Williams RJ
Diagn Microbiol Infect Dis; 2017 Apr; 87(4):376-381. PubMed ID: 28087171
[TBL] [Abstract][Full Text] [Related]
9. Use of in vitro critical inhibitory concentration, a novel approach to predict in vivo synergistic bactericidal effect of combined amikacin and piperacillin against Pseudomonas aeruginosa in a systemic rat infection model.
Chan E; Zhou S; Srikumar S; Duan W
Pharm Res; 2006 Apr; 23(4):729-41. PubMed ID: 16554956
[TBL] [Abstract][Full Text] [Related]
10. Influence of borderline cefepime MIC on the outcome of cefepime-susceptible Pseudomonas aeruginosa bacteremia treated with a maximal cefepime dose: a hospital-based retrospective study.
Su TY; Ye JJ; Yang CC; Huang CT; Chia JH; Lee MH
Ann Clin Microbiol Antimicrob; 2017 Jul; 16(1):52. PubMed ID: 28738848
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome.
Joo EJ; Kang CI; Ha YE; Kang SJ; Park SY; Chung DR; Peck KR; Lee NY; Song JH
Microb Drug Resist; 2011 Jun; 17(2):305-12. PubMed ID: 21381966
[TBL] [Abstract][Full Text] [Related]
12. Time above the MIC of Piperacillin-Tazobactam as a Predictor of Outcome in Pseudomonas aeruginosa Bacteremia.
Tannous E; Lipman S; Tonna A; Hector E; Hussein Z; Stein M; Reisfeld S
Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32482679
[No Abstract] [Full Text] [Related]
13. Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis.
Kuti JL; Nightingale CH; Quintiliani R; Nicolau D
Diagn Microbiol Infect Dis; 2002 Sep; 44(1):51-7. PubMed ID: 12376031
[TBL] [Abstract][Full Text] [Related]
14. Pseudomonas aeruginosa bloodstream infections in children: a 9-year retrospective study.
Pilmis B; Alby-Laurent F; Fasola ML; Seegers V; Guery R; Guet-Revillet H; Postaire M; Toubiana J; Bille E; Lortholary O; Zahar JR
Eur J Pediatr; 2020 Aug; 179(8):1247-1254. PubMed ID: 32080759
[TBL] [Abstract][Full Text] [Related]
15. [Pseudomonas aeruginosa bacteremia: associations with a source of infection and antibiotic resistance].
Dambrauskiene A; Adukauskiene D; Jeroch J; Vitkauskiene A
Medicina (Kaunas); 2009; 45(1):1-7. PubMed ID: 19223699
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia.
Bowers DR; Liew YX; Lye DC; Kwa AL; Hsu LY; Tam VH
Antimicrob Agents Chemother; 2013 Mar; 57(3):1270-4. PubMed ID: 23263001
[TBL] [Abstract][Full Text] [Related]
17. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
Lee CH; Su TY; Ye JJ; Hsu PC; Kuo AJ; Chia JH; Lee MH
J Microbiol Immunol Infect; 2017 Oct; 50(5):677-683. PubMed ID: 26188977
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of children with enterobacteriaceae bacteremia with reduced susceptibility to ceftriaxone: do the revised breakpoints translate to improved patient outcomes?
Tamma PD; Wu H; Gerber JS; Hsu AJ; Tekle T; Carroll KC; Cosgrove SE
Pediatr Infect Dis J; 2013 Sep; 32(9):965-9. PubMed ID: 23470679
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa.
Crandon JL; Bulik CC; Kuti JL; Nicolau DP
Antimicrob Agents Chemother; 2010 Mar; 54(3):1111-6. PubMed ID: 20038614
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa.
Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
Microb Drug Resist; 2005; 11(1):68-74. PubMed ID: 15770098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
